Business
Taysha Gene Therapies to Release Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10
DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and
About this update from Taysha Gene Therapies, Inc.
[{"type":"text","content":" DALLAS--(BUSINESS WIRE)--\nTaysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the third quarter ended September 30, 2021, and host a corporate update conference call and webcast on Wednesday, November 10, 2021, at 8:00 AM Eastern Time.\n\n\nConference Call Details\n\n\nWednesday, November 10, at 8:00 AM Eastern Time / 7:00 AM Central Time\n\n\n\nToll Free:\n\n\n\n\n877-407-0792\n\n\n\n\n\nInternational:\n\n\n\n\n201-689-8263\n\n\n\n\n\nConference ID:\n\n\n\n\n13723855\n\n\n\n\n\nWebcast:\n\n\n\n\nhttps://ir.tayshagtx.com/news-events/events-presentations\n\n\n\n\nAn archived version of the webcast will be available on Taysha’s website for 30 days.\n\nAbout Taysha Gene Therapies\n\nTaysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20211103005348/en/\n\nCompany Contact:\nKimberly Lee, D.O.\nSVP, Corporate Communications and Investor Relations\nTaysha Gene Therapies\[email protected]\n\nMedia Contact:\nCarolyn Hawley\nCanale Communications\[email protected]\n\nSource: Taysha Gene Therapies, Inc.","length":5075,"tagName":"div"}]